Erythrodermic Psoriasis in the Context of Emerging Triggers: Insights into Dupilumab-Associated and COVID-19-Induced Psoriatic Disease

This study investigates the potential triggers of erythrodermic psoriasis (EP), particularly focusing on the roles of SARS-CoV-2, COVID-19 vaccination, and dupilumab therapy. It presents a case of a 70-year-old male who developed EP after starting dupilumab, suggesting that both SARS-CoV-2 and dupilumab may share inflammatory pathways that exacerbate psoriasis. The research highlights the need for further studies to understand these relationships and improve management strategies for complex psoriasis cases. Additionally, it discusses how COVID-19 and its vaccines can exacerbate or induce psoriasis through immune dysregulation, emphasizing the importance of understanding the immunological pathways to enhance treatment strategies.